Danaher Acquires Aldevron for $9.6 Billion

EQT VIII to Acquire Majority Interest in Aldevron

July 31, 2019

Biotechnology

EQT VIII has entered into an agreement to acquire a majority interest in Aldevron, a Fargo-based global supplier of plasmid DNA and other biologics, with founders, management and TA Associates retaining minority stakes. EQT will support Aldevron's growth through investments in production capacity, R&D and international expansion as the company continues to serve the gene therapy and broader biopharma markets.

Novo Nordisk Acquires Dicerna Pharmaceuticals

November 18, 2021

Biotechnology

Novo Nordisk agreed to acquire Dicerna Pharmaceuticals for $38.25 per share, representing an enterprise equity value of approximately $3.3 billion, to expand its RNAi capabilities. The acquisition builds on a 2019 research collaboration and brings Dicerna's GalXC RNAi platform and pipeline into Novo Nordisk to accelerate development of RNAi therapeutics across cardiometabolic, liver and rare disease indications. The tender offer completed in December 2021 and Dicerna is now a wholly owned subsidiary of Novo Nordisk.

Danaher Corporation Acquires Abcam plc

August 28, 2023

Biotechnology

Danaher Corporation agreed to acquire Abcam plc for $24.00 per share, representing an enterprise value of approximately $5.7 billion including assumed indebtedness. Abcam, headquartered in Cambridge, United Kingdom, will operate as a standalone company within Danaher's Life Sciences segment; the transaction is expected to close in mid-2024 and is subject to customary approvals.

Danaher Corporation Acquires Genedata AG

August 19, 2024

Software

Danaher Corporation has acquired Genedata AG, a Basel-based provider of software solutions for biopharmaceutical R&D, and will integrate the company into its Life Sciences segment. The acquisition expands Danaher’s R&D workflow capabilities by adding Genedata’s data-driven informatics and automation tools to accelerate drug discovery and development.

Merck Acquires Acceleron Pharma for $11.5 Billion

September 30, 2021

Biotechnology

Merck has entered into a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. The acquisition brings Acceleron's late-stage sotatercept program (for pulmonary arterial hypertension) and its REBLOZYL portfolio into Merck's cardiovascular pipeline, subject to tender offer completion and customary regulatory approvals.

AbbVie Acquires Aliada Therapeutics for $1.4 Billion

December 11, 2024

Biotechnology

AbbVie has completed the $1.4 billion acquisition of Aliada Therapeutics, a RA Capital- and JJDC-backed biotech developing ALIA-1758, an anti‑pyroglutamate amyloid beta antibody that uses a blood‑brain‑barrier crossing technology for Alzheimer's disease. The deal brings Aliada's CNS drug‑delivery platform and lead Phase 1 asset into AbbVie's neuroscience pipeline and represents an exit for RA Capital's Raven incubator and other early investors.